It started in the group chat, same as everything else. One of you got the patch. Another got the gel. The third one said her doctor looked at her like she'd asked for a jet ski.

Testosterone for women is the third hormone of the 2020s, after estrogen and progesterone, the one nobody explained to you when they explained the first two. And right now it's being sold with the enthusiasm of a supplement and the evidence standards of one too. So let's do the boring, clarifying part: what it actually fixes, who qualifies, how the prescription game works, and which parts of the hype are just hype.

What it actually fixes: one thing, not five

Here's the sentence that saves you a year of internet: the only evidence-based indication for testosterone therapy in women is hypoactive sexual desire disorder, clinically significant low sexual desire that bothers you. That's it. That's the list.

The Global Consensus Position Statement on the Use of Testosterone Therapy for Women, endorsed by the International Menopause Society, The Endocrine Society, the North American Menopause Society, and the Royal College of Obstetricians and Gynaecologists, is explicit: testosterone is the only evidence-based use, and "there are insufficient data for using testosterone for any other symptom/condition or for disease prevention" Established: Global Consensus Position Statement.

Read that twice, because it's doing heavy lifting against the entire wellness-industrial complex. The TikTok version says testosterone fixes brain fog, fatigue, mood, motivation, body composition, and your husband's attitude. The position statement, written by the actual researchers who ran the actual trials, says: desire. One domain. If a clinic is promising you a brain-fog transplant and a new personality, they are selling you something the evidence doesn't back.

Does that mean T does nothing for energy? It means we don't have the trials to say it does, and the people who wrote the guidelines looked and didn't find enough. If a clinician offers testosterone for brain fog, that's not cutting-edge; that's off-book.

Who qualifies

The evidence-backed candidate is: a postmenopausal woman, natural or surgical, with low sexual desire that is bothering her, that isn't better explained by something else, and that hasn't resolved with hormone therapy alone.

The UK's NICE guideline, which is the clearest plain-language version of this, says: "Consider testosterone supplementation for people with low sexual desire associated with menopause if HRT alone is not effective" Established: NICE NG23. Two qualifiers hiding in that sentence: low sexual desire and after HRT alone didn't fix it. That's the order of operations. Estrogen and progesterone first. Testosterone is not the starter; it's the follow-up.

The gatekeeping game ("you have to say low libido")

Here's the lore, and it's mostly true, and it's not a conspiracy: the prescription conversation starts with desire. Not energy, not brain fog, not "general vitality." Clinicians who prescribe testosterone for women have one evidence-backed door, and the door is labeled low libido. Women who want the energy benefits, which may or may not exist, quickly learn to say the magic words.

Is that gatekeeping? Sort of. It's also just the evidence being honest with itself. The trials measured desire. The guidelines can only green-light what was studied. So yes, in practice, "you have to say low libido" is real. The sharper version is: the only honest, evidence-backed reason to be in that room is low libido anyway. If that's genuinely not your issue, the answer to "can I get testosterone" is supposed to be "the data doesn't support it", and if a clinic nods along to brain fog and writes the script anyway, run a little faster, because they're playing loose with the evidence you're putting in your body.

Gel and patch before injection (this is a rule, not a preference)

When testosterone is prescribed for women, it's in doses that approximate physiological premenopausal levels, roughly a tenth of what men get. And the consensus position is blunt about what that rules out: "Use of any testosterone preparation that results in supraphysiologic concentrations of testosterone, including pellets and injections, is not recommended" Established: Global Consensus Position Statement.

So the clinic-adjacent internet lore is right: gel or patch first. Transdermal, low-dose, physiological. Pellets and injections, the stuff that produces male-range peaks, are the red-flag zone. Any provider who leads with "we'll start you on injections" is leading with the thing the international consensus explicitly says not to do.

And the monitoring plan is not optional: a baseline level before starting, a repeat 3–6 weeks after starting, then a level every six months to screen for overuse, plus watching for signs of androgen excess Established: Global Consensus Position Statement. If nobody is measuring anything, they're not following the playbook.

Venous vs finger-prick testing: the test that can't tell you anything

Now the part that confuses everyone, including some doctors: there is no blood level that diagnoses low desire. The consensus statement is explicit that no measured androgen cutoff separates women with sexual dysfunction from women without it Established: Global Consensus Position Statement. The diagnosis is clinical, it's your history, your distress, your story. A number on a lab slip does not do the diagnosing.

But testing still matters for a different job: ruling out supraphysiologic levels before and during treatment. And here's where the finger-prick trend dies: direct assays for total and free testosterone are "highly unreliable in the female range." That's the consensus statement's own grade-A finding. Women's testosterone levels sit at the bottom of the measuring scale, where standard direct assays, the kind in most finger-prick home kits and many routine labs, are at their worst. The reliable method is liquid/gas chromatography with tandem mass spectrometry, usually written LC-MS/MS, which is a venous draw to a lab that runs that assay Established: Global Consensus Position Statement.

Translation: a finger-prick kit that promises to "find your low testosterone" is selling you a number that the assay can't reliably produce at your concentration. If you're going to measure, measure venous, at a lab using LC-MS/MS, and use the result to screen for overuse, not to "confirm" a diagnosis your clinician should already have made from your history.

The NHS wait, the private boom, and who's paying

This is where the UK reality bites. NICE says "consider", but in practice, getting someone to actually prescribe unlicensed testosterone on the NHS can mean long waits and a referral merry-go-round. Women report wait times that stretch toward a year for specialist menopause services, which is why the private clinic market is booming and why the online pharmacy "T for women" lane is suddenly everywhere. (We're describing the market reality women report, not sourcing the wait times to a guideline, the guidelines don't have a wait-time clause.)

The private boom is a double-edged sword: it's how a lot of women finally get heard, and it's also where the evidence gets laundered into a lifestyle product. Private clinics are not automatically bad. But the ones that sell testosterone for brain fog, sell it on a finger-prick result, or skip the "HRT first" step are selling the version of the story the consensus statement explicitly corrected.

Risks, honestly

At physiological doses, the trial data say the side effects are real but modest: mild increases in acne and body/facial hair growth in some women, and notably not alopecia, clitoromegaly, or voice change at those doses Established: Global Consensus Position Statement.

The bigger-ticket items are where the data run out. Oral testosterone is associated with adverse lipid changes, which is part of why transdermal is the route. On breast health: short-term transdermal use doesn't increase mammographic density, but the trials are insufficient to assess long-term breast cancer risk, and caution is recommended for women with hormone-sensitive breast cancer Established: Global Consensus Position Statement. Anyone telling you "zero risk, no studies needed" is not reading the same statement.

The six-month rule, which is the most useful sentence in this article

The consensus position has a built-in test of whether it's working, and it's wonderfully unsentimental: if you experience no benefit within six months, treatment should be stopped Established: Global Consensus Position Statement.

That's the whole game. Testosterone for women isn't a lifestyle subscription; it's a trial with a defined endpoint. Six months, honest review, stop if it didn't do the one thing it's supposed to do. If your clinic can't tell you what the six-month rule is, or schedules your "vitality maintenance" before your first review, you have your answer about what they're running.

The takeaway, in four lines

  1. The only evidence-backed use is low sexual desire, not brain fog, not energy.
  2. HRT (estrogen/progesterone) comes first; testosterone is the follow-up, not the starter.
  3. Physiological doses, transdermal, with real monitoring, injections and pellets are the red flag.
  4. Diagnosis is your history, not a finger-prick number. If no benefit in six months, stop.

The third hormone is real, it helps some women with a real and under-discussed problem, and it's currently being oversold. Both things are true. The evidence is the only thing standing between you and a very expensive bottle of vibes, and now you've read it.

Related: The HRT End Game: how long you actually take it · Allegra + Pepcid for hot flashes: the viral shortcut, checked · Hormone therapy questions to ask a qualified clinician